Acute Lymphoblastic Leukemia (ALL) is a malignant neoplasm characterized by the uncontrolled proliferation of immature lymphoid progenitor cells (lymphoblasts) in the bone marrow. These malignant cells crowd out normal hematopoiesis, leading to bone marrow failure. ALL is the most common pediatric malignancy, though it occurs in adults, typically carrying a poorer prognosis in the latter group.

ALL is primarily driven by somatic mutations that dysregulate cell cycle control, differentiation, and apoptosis in lymphoid progenitors. Genetic factors include chromosomal translocations (e.g., BCR-ABL1, ETV6-RUNX1). Environmental factors, including exposure to high-dose ionizing radiation and certain chemical toxins (benzene), may contribute.

The process begins with a "leukemic hit" in a pluripotent hematopoietic stem cell or a lymphoid progenitor. This results in the production of immature lymphoblasts that lack the ability to differentiate into mature lymphocytes. These blasts accumulate in the bone marrow, disrupting normal red cell, white cell, and platelet production. They subsequently infiltrate the blood, lymph nodes, spleen, liver, and central nervous system (CNS).

ALL accounts for approximately 75% of childhood leukemias, with a peak incidence between ages 2 and

1. It is more common in males than females and shows a higher prevalence in Hispanic populations.

Genetic syndromes (Down syndrome, Li-Fraumeni syndrome), ionizing radiation, chemotherapy exposure, and immune system deficiencies.

A. Early Symptoms: Fatigue, unexplained fever, night sweats.
B. Common Symptoms: Pale skin, easy bruising or bleeding, bone/joint pain.
C. Advanced Symptoms: Hepatomegaly, splenomegaly, generalized lymphadenopathy.
D. Emergency Symptoms: Superior vena cava syndrome, CNS involvement (seizures, headache), severe neutropenic sepsis.

Pallor (anemia), petechiae/ecchymosis (thrombocytopenia), cervical or axillary lymphadenopathy, abdominal tenderness (splenomegaly/hepatomegaly), and bone tenderness.

A. Clinical Assessment: Comprehensive physical exam.
B. Laboratory Testing: CBC with differential, peripheral blood smear.
C. Imaging Studies: Chest X-ray (mediastinal mass), PET/CT.
D. Functional Tests: Lumbar puncture for CNS blast evaluation.
E. Biopsy Findings: Bone marrow aspiration showing >20% blasts.
F. Genetic Testing: Cytogenetics (FISH, karyotype) and PCR for fusion genes.
G. Differential Diagnosis: AML, Lymphoma, Aplastic anemia.

Test Name: Complete Blood Count (CBC)
Type: Blood Test
Purpose: Assess cell counts
Expected Findings: Anemia, thrombocytopenia, abnormal WBC count
Interpretation: Indicates bone marrow suppression